SCHEMBL29173475

SCHEMBL29173475

COC(=O)c1nc(-c2cncc3c2ncn3C)c(C2CC2)nc1Nc1ccc(N2CCOCC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 4/20 0.40
▸ CDK4 P11802 3/20 0.40
▸ CDK1 P06493 2/20 0.40
▸ CCNB1 P14635 2/20 0.40
▸ CCND1 P24385 2/20 0.40
▸ CCNE1 P24864 2/20 0.40
▸ ALK Q9UM73 4/20 0.39
▸ LCK P06239 1/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ INSR P06213 1/20 0.39
▸ EML4 Q9HC35 3/20 0.38
▸ PKMYT1 Q99640 2/20 0.38
▸ LRRK2 Q5S007 2/20 0.37
▸ SYK P43405 4/20 0.37
▸ FLT3 P36888 2/20 0.36
▸ ABL1 P00519 2/20 0.36
▸ NTRK1 P04629 2/20 0.36
▸ YES1 P07947 2/20 0.36
▸ KDR P35968 2/20 0.36
▸ CCNA2 P20248 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30206250 1.00 CDK2 (0.40) CDK2CDK4CDK1CCNB1CCND1
SCHEMBL29173457 0.95 CDK2 (0.39) CDK2CDK4CDK1CCNB1CCND1
SCHEMBL30206144 0.95 CDK2 (0.39) CDK2CDK4CDK1CCNB1CCND1
SCHEMBL30205510 0.92 EML4 (0.47) CDK2CDK4ALKLCKJAK3
SCHEMBL24944955 0.92 EML4 (0.47) CDK2CDK4ALKLCKJAK3
SCHEMBL30205974 0.90 CDK1 (0.39) CDK2CDK4CDK1CCNB1CCND1
SCHEMBL29173625 0.90 CDK1 (0.39) CDK2CDK4CDK1CCNB1CCND1
SCHEMBL30206147 0.90 PKMYT1 (0.41) CDK2CDK4ALKJAK3INSR
SCHEMBL30206202 0.89 PKMYT1 (0.40) CDK2CDK4CDK1CCNB1CCND1
SCHEMBL29173512 0.89 PKMYT1 (0.40) CDK2CDK4CDK1CCNB1CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
Send feedback